Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer.

Shingo MaedaTomoki MotegiAki IioKenjiro KajiYuko Goto-KoshinoShotaro EtoNamiko IkedaTakayuki NakagawaRyohei NishimuraTomohiro YonezawaYasuyuki Momoi

Published in: Journal for immunotherapy of cancer (2022)

Anti-Treg treatment, through CCR4 blockade, may be a promising therapeutic approach for advanced prostate cancer in dogs and some population of human patients.

Keyphrases

regulatory t cells
prostate cancer
dendritic cells
radical prostatectomy
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis